Cargando…

Functional Gene Expression Signatures from On-Treatment Tumor Specimens Predict Anti-PD1 Blockade Response in Metastatic Melanoma

Functional gene expression signatures (FGES) from pretreatment biopsy samples have been used to predict the responses of metastatic melanoma to immune checkpoint blockade (ICB) therapies. However, there are no predictive FGE signatures from patients receiving treatment. Here, using the Elastic Net R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Shuzhao, Zhang, Limei, Lin, Haocheng, Liang, Yang, Wang, Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855743/ https://www.ncbi.nlm.nih.gov/pubmed/36671443 http://dx.doi.org/10.3390/biom13010058

Ejemplares similares

Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma
por: Du, Kuang, et al.
Publicado: (2021)

PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma
por: Parakh, Sagun, et al.
Publicado: (2021)

Comprehensive analysis of glycoprotein VI-mediated platelet activation signaling pathway for predicting pan-cancer survival and response to anti-PD-1 immunotherapy
por: Chen, Shuzhao, et al.
Publicado: (2023)

A tumor-associated endothelial signature score model in immunotherapy and prognosis across pan-cancers
por: Chen, Shuzhao, et al.
Publicado: (2023)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
por: Ascierto, Paolo A., et al.
Publicado: (2019)

Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma
por: Shi, Guilan, et al.
Publicado: (2022)

Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
por: Wang, Meihua, et al.
Publicado: (2019)

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
por: Bertrand, Florie, et al.
Publicado: (2017)

Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma
por: Cui, Chuanliang, et al.
Publicado: (2021)

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
por: Liu, David, et al.
Publicado: (2019)

Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy
por: Herbreteau, Guillaume, et al.
Publicado: (2018)

Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent anti-tumor immunity in melanoma
por: Jacquelot, Nicolas, et al.
Publicado: (2021)

PD-1 Blockade on Tumor Microenvironment-Resident ILC2s Promotes TNF-α Production and Restricts Progression of Metastatic Melanoma
por: Howard, Emily, et al.
Publicado: (2021)

Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study
por: Herbreteau, Guillaume, et al.
Publicado: (2021)

PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2020)

Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma
por: Frias, Alex, et al.
Publicado: (2023)

FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy
por: Flaus, A., et al.
Publicado: (2021)

Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
por: Lau, Doreen, et al.
Publicado: (2021)

Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
por: Liu, David, et al.
Publicado: (2020)

High response rate to PD-1 blockade in desmoplastic melanomas
por: Eroglu, Zeynep, et al.
Publicado: (2018)

IFN-γ blockade after genetic inhibition of PD-1 aggravates skeletal muscle damage and impairs skeletal muscle regeneration
por: Zhuang, Shuzhao, et al.
Publicado: (2023)

A time course-dependent metastatic gene expression signature predicts outcome in human metastatic melanomas
por: Chen, Rongyi, et al.
Publicado: (2014)

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
por: Zhao, Mingxia, et al.
Publicado: (2019)

A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma
por: Huang, Alexander C., et al.
Publicado: (2019)

Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma
por: Dawidowska, Anna, et al.
Publicado: (2022)

PD-L1 blockade enhances anti-tumor efficacy of NK cells
por: Oyer, Jeremiah L., et al.
Publicado: (2018)

PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy
por: Zahm, Christopher D., et al.
Publicado: (2021)

Bv8 Blockade Sensitizes Anti-PD1 Therapy Resistant Tumors
por: Benguigui, Madeleine, et al.
Publicado: (2022)

PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates
por: Pico de Coaña, Yago, et al.
Publicado: (2020)

TYRO3 blockade enhances anti-PD-1 therapy response by modulating expression of CCN1 in tumor microenvironment
por: Park, Miso, et al.
Publicado: (2023)

Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
por: Placke, Jan-Malte, et al.
Publicado: (2021)

Inflammatory and Nutritional Scoring System for Predicting Prognosis in Patients with Newly Diagnosed Multiple Myeloma
por: Zhang, Limei, et al.
Publicado: (2023)

Anti‐PD‐1 antibodies in metastatic uveal melanoma: a treatment option?
por: Bender, Carolin, et al.
Publicado: (2017)

Comparing the associations between host and tumor factors with survival outcomes with anti‐PD‐1 immunotherapy in metastatic melanoma
por: Koczka, Kim, et al.
Publicado: (2022)

PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV
por: Davar, Diwakar, et al.
Publicado: (2015)

Blockade of Tumor-Expressed PD-1 promotes lung cancer growth
por: Du, Shisuo, et al.
Publicado: (2018)

Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade–resistant Melanoma for Anti-PD-L1 Rechallenge
por: van der Westhuizen, Andre, et al.
Publicado: (2022)

Identification of 15 lncRNAs Signature for Predicting Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1 Monotherapy
por: Zhou, Jian-Guo, et al.
Publicado: (2021)

Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma
por: Werner, Jan-Michael, et al.
Publicado: (2019)

A gene expression signature associated with survival in metastatic melanoma
por: Mandruzzato, Susanna, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_f5ml8gfr1dkr9cmqdlpmmasl0a